company background image
ESP

Esperite ENXTAM:ESP Stock Report

Last Price

€0.022

Market Cap

€1.2m

7D

11.0%

1Y

-33.1%

Updated

07 Aug, 2022

Data

Company Financials
ESP fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

ESP Stock Overview

Esperite N.V., together with its subsidiaries, operates as a regenerative and predictive medicine company in the Netherlands, Spain, Italy, Switzerland, and internationally.

Esperite Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Esperite
Historical stock prices
Current Share Price€0.022
52 Week High€0.038
52 Week Low€0.015
Beta0
1 Month Change5.71%
3 Month Change-9.02%
1 Year Change-33.13%
3 Year Change-66.36%
5 Year Change-95.63%
Change since IPO-99.67%

Recent News & Updates

Shareholder Returns

ESPNL BiotechsNL Market
7D11.0%0.2%-0.6%
1Y-33.1%-15.3%-14.5%

Return vs Industry: ESP underperformed the Dutch Biotechs industry which returned -15.3% over the past year.

Return vs Market: ESP underperformed the Dutch Market which returned -14.5% over the past year.

Price Volatility

Is ESP's price volatile compared to industry and market?
ESP volatility
ESP Average Weekly Movement8.8%
Biotechs Industry Average Movement8.1%
Market Average Movement5.1%
10% most volatile stocks in NL Market8.1%
10% least volatile stocks in NL Market3.1%

Stable Share Price: ESP is more volatile than 90% of Dutch stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: ESP's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Dutch stocks.

About the Company

FoundedEmployeesCEOWebsite
2000n/aFrédéric Amarhttps://www.esperite.com

Esperite N.V., together with its subsidiaries, operates as a regenerative and predictive medicine company in the Netherlands, Spain, Italy, Switzerland, and internationally. It operates through four segments: Stem Cell, The Cell Factory, Genoma, and Other. The company collects, processes, and stores human adult stem cells from the umbilical cord blood and the umbilical cord.

Esperite Fundamentals Summary

How do Esperite's earnings and revenue compare to its market cap?
ESP fundamental statistics
Market Cap€1.16m
Earnings (TTM)-€18.72m
Revenue (TTM)€13.57m

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ESP income statement (TTM)
Revenue€13.57m
Cost of Revenue€4.50m
Gross Profit€9.07m
Other Expenses€27.78m
Earnings-€18.72m

Last Reported Earnings

Jun 30, 2018

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did ESP perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is ESP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ESP?

Other financial metrics that can be useful for relative valuation.

ESP key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does ESP's PB Ratio compare to its peers?

ESP PB Ratio vs Peers
The above table shows the PB ratio for ESP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average3.7x
VVY Vivoryon Therapeutics
11.1x71.8%€183.0m
PHARM Pharming Group
3x33.4%€585.9m
HXL Hexima
0.2x58.1%AU$2.0m
RHOVAC RhoVac
0.5xn/akr15.2m
ESP Esperite
n/an/a€1.2m

Price-To-Book vs Peers: Insufficient data to calculate ESP's Price-To-Book Ratio vs. peers for valuation analysis.


Price to Earnings Ratio vs Industry

How does ESP's PE Ratio compare vs other companies in the European Biotechs Industry?

Price-To-Book vs Industry: Insufficient data to calculate ESP's Price-To-Book Ratio vs. industry for valuation analysis.


Price to Book Ratio vs Fair Ratio

What is ESP's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ESP PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ration/a
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ESP's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of ESP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ESP's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ESP's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

  • Take a look at our analysis of ESP's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Esperite regulatory filings.

Future Growth

How is Esperite forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


42.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Esperite has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Take a look at our analysis of ESP’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Esperite competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Esperite performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


21.4%

Historical Pharmaceuticals & Biotech annual earnings growth

In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Esperite has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Discover strong past performing companies

  • When a company lacks a financial track record, its management’s track record becomes important. Corporate governance also plays an important role in a young business as board members are seen as highly-experienced leaders to help steer the company into the future. Take a look at Esperite's management and board experience and expertise to assess their ability to deliver on their strategic promises.

Financial Health

How is Esperite's financial position?

Financial Health Score

0/6

Financial Health Score 0/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

In this section we usually analyse Esperite's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Esperite has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Discover healthy companies

  • Take a look at our analysis of ESP’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. Esperite's cash and debt levels may be found in its annual reports archived here.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Esperite's financial data was last updated here.

Dividend

What is Esperite current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ESP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ESP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ESP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ESP's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: ESP is not paying a notable dividend for the Dutch market.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ESP has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

8.6yrs

Average board tenure


CEO

Frédéric Amar (58 yo)

8.42yrs

Tenure

€510,000

Compensation

Mr. Frédéric A. Amar has been Chief Executive Officer and Executive Director of Esperite N.V. (Formerly Cryo-Save Group N.V.) since March 19, 2014 and served as its Non Executive Director since November 20...


CEO Compensation Analysis

Compensation vs Market: Insufficient data to establish whether Frédéric's total compensation is reasonable compared to companies of similar size in the Dutch market.

Compensation vs Earnings: Insufficient data to compare Frédéric's compensation with company performance.


Board Members

Experienced Board: ESP's board of directors are considered experienced (8.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Esperite N.V.'s employee growth, exchange listings and data sources


Key Information

  • Name: Esperite N.V.
  • Ticker: ESP
  • Exchange: ENXTAM
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: €1.162m
  • Shares outstanding: 52.33m
  • Website: https://www.esperite.com

Number of Employees


Location

  • Esperite N.V.
  • Herengracht 282
  • Amsterdam
  • Noord-Holland
  • 1016 BX
  • Netherlands

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/07 00:00
End of Day Share Price2022/08/05 00:00
Earnings2018/06/30
Annual Earnings2017/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.